TW200740999A - Therapeutic reprogramming of germ-line stem cells - Google Patents

Therapeutic reprogramming of germ-line stem cells

Info

Publication number
TW200740999A
TW200740999A TW095126067A TW95126067A TW200740999A TW 200740999 A TW200740999 A TW 200740999A TW 095126067 A TW095126067 A TW 095126067A TW 95126067 A TW95126067 A TW 95126067A TW 200740999 A TW200740999 A TW 200740999A
Authority
TW
Taiwan
Prior art keywords
germ
stem cells
line stem
therapeutic reprogramming
reprogramming
Prior art date
Application number
TW095126067A
Other languages
English (en)
Chinese (zh)
Inventor
Chauncey B Sayre
Francisco J Silva
Kwok-Yuen F Pau
Original Assignee
Primegen Biotech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Primegen Biotech Llc filed Critical Primegen Biotech Llc
Publication of TW200740999A publication Critical patent/TW200740999A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0608—Germ cells
    • C12N5/0611—Primordial germ cells, e.g. embryonic germ cells [EG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/235—Leukemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C12N2501/392—Sexual steroids

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW095126067A 2005-07-15 2006-07-17 Therapeutic reprogramming of germ-line stem cells TW200740999A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69968005P 2005-07-15 2005-07-15
US27961106A 2006-04-13 2006-04-13

Publications (1)

Publication Number Publication Date
TW200740999A true TW200740999A (en) 2007-11-01

Family

ID=37398728

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095126067A TW200740999A (en) 2005-07-15 2006-07-17 Therapeutic reprogramming of germ-line stem cells

Country Status (6)

Country Link
EP (1) EP1904623A1 (fr)
JP (1) JP2009502124A (fr)
AU (1) AU2006269884A1 (fr)
CA (1) CA2615396A1 (fr)
TW (1) TW200740999A (fr)
WO (1) WO2007012009A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8173118B2 (en) 2004-07-30 2012-05-08 Mayo Foundation For Medical Education And Research Compositions consisting essentially of TGF-β, BMP-2 FGF-4, leukemia inhibitory factor, IGF-1, IL-6 and H-α-thrombin
WO2007115216A1 (fr) * 2006-03-30 2007-10-11 Primegen Biotech Llc Reprogrammation de cellules souches testiculaires d'humains adultes en cellules souches pluripotentes de la lignee germinale
US9765298B2 (en) 2006-07-24 2017-09-19 Mayo Foundation For Medical Education And Research Methods and materials for providing cardiac cells
CN100577798C (zh) * 2007-01-30 2010-01-06 中国人民解放军军事医学科学院基础医学研究所 细胞因子和化合物构成的组方，其促进神经再生作用及在神经系统疾患研究和诊治中的作用
WO2009145761A1 (fr) 2008-05-27 2009-12-03 Mayo Foundation For Medical Education And Research Procédés et matériaux destinés à utiliser des cellules dans le traitement du tissu cardiaque
JP6276918B2 (ja) 2009-11-12 2018-02-07 テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド 多能性幹細胞を未分化状態で培養する培地、細胞培養および方法
CN102486475B (zh) * 2011-09-27 2015-12-02 西比曼生物科技（香港）有限公司 一种自体脂肪干细胞抗衰老效果的评价方法
RU2691027C2 (ru) * 2011-12-05 2019-06-07 Фэктор Байосайенс Инк. Способы и препараты для трансфекции клеток
WO2013100140A1 (fr) * 2011-12-29 2013-07-04 国立大学法人 京都大学 Induction de cellules souches pluripotentes à partir de cellules germinales
CA2957532A1 (fr) * 2014-08-07 2016-02-11 Duke University Compositions et procedes de reprogrammation de cellules, telles que des fibroblastes, en cardiomyocytes
CN112322581B (zh) * 2020-09-14 2023-05-12 生物岛实验室 组合物及其应用、细胞培养基及间充质干细胞的复苏方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2248142A1 (fr) * 1996-03-12 1997-09-18 Life Technologies, Inc. Additif pour milieu de culture nutritif pour cellules hematopoietiques
US20020136709A1 (en) * 2000-12-12 2002-09-26 Nucleus Remodeling, Inc. In vitro-derived adult pluripotent stem cells and uses therefor
WO2005100548A1 (fr) * 2004-03-30 2005-10-27 Kyoto University Procédé de fabrication d'une cellule souche pluripotente provenant d'une cellule androgène

Also Published As

Publication number Publication date
AU2006269884A1 (en) 2007-01-25
JP2009502124A (ja) 2009-01-29
EP1904623A1 (fr) 2008-04-02
CA2615396A1 (fr) 2007-01-25
WO2007012009A1 (fr) 2007-01-25

Similar Documents

Publication Publication Date Title
TW200740999A (en) Therapeutic reprogramming of germ-line stem cells
TW200720232A (en) Crystalline solid forms of tigecycline and methods of preparing same
MX2009013706A (es) Celulas multipotentes/pluripotentes y metodos relacionados.
HN2005029978A (es) Formulaciones
MX2007003378A (es) Control de parasitos en animales mediante el uso de nuevos derivados de trifluorometansulfonanilida oxima eter.
WO2010124142A3 (fr) Compositions cellulaires issues de cellules reprogrammées dédifférenciées
HK1112483A1 (zh) 體外製備腫瘤細胞以激活自然殺傷細胞的方法
CR20110477A (es) Inhibidores de enzimas de proteina cinasa activadas por mitogeno p38
WO2010111422A3 (fr) Génération de cellules souches pluripotentes induites en utilisant deux facteurs et l'inactivation de p53
MX2007001638A (es) Proteinas de fusion del dominio de unión.
TW200720256A (en) IL-12 modulatory compounds
WO2011071476A3 (fr) Compositions et procédés de génie cellulaire
WO2006026570A8 (fr) Utilisation de cellules souches pour generer des cellules de l'oreille interne
WO2010022395A3 (fr) Procédés de reprogrammation de cellules
HK1136847A1 (en) Targeted integration into the ppp1r12c locus
MX2022009759A (es) El uso de 1-(4-ciano-3-trifluorometil-fenil)-3-[7-(4-ciano-3-trifl uorometil-fenil)-6-tioxo-5-p-tolilo-5,7-diazaespiro[3.4]oct-8-ili deno]-tiourea.
DK1948789T3 (da) Fremgangsmåde til fremstilling af permanente, humane cellelinjer
SG166770A1 (en) Use of adipose tissue-derived stromal stem cells in treating fistula
IL185253A (en) Cytoquenols are preserved in spirocetal, a process for their preparation, preparations containing them and methods for their use in the control of pests
WO2006052646A3 (fr) Derivation de cellules souches embryonnaires
WO2007120842A3 (fr) Procedes et compositions destines a cibler le c-rel
WO2010062762A3 (fr) Compositions et procédés de réduction des signes du vieillissement de la peau
WO2005108428A3 (fr) Variants d'epissage de cd40 et leurs utilisations
HK1136557A1 (fr)
NO20062709L (no) Stamceller som er egnet for transplantasjon, fremstilling derav og farmasoytiske preperater omfattende nevnte stamceller